Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

- 1 min read

Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Technology

Cambridge, MA, March 1, 2023 (PRNewswire) -- Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the completion of a $135 million Series B financing led by GV (Google Ventures), with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors.

Read full article here.

Recent Posts

See All

Alterome Therapeutics Raises $132M Led by Goldman Sachs for Precision Oncology Initiatives

San Diego, CA, April 3, 2024 (Reuters) -- Alterome Therapeutics announced that it has successfully secured $132 million. Spearheaded by Goldman Sachs Alternatives, this a series B financing brings f

Zura Bio Announces Robert Lisicki as CEO and Director

Henderson, NV, April 8, 2024 (Zura Bio) -- Zura Bio, a company focused on advancing treatments for autoimmune and inflammatory conditions, has named Robert Lisicki as its new Chief Executive Officer

Obsidian Therapeutics Secures $160.5M Series C Funding for Advancement of OBX-115 Clinical Trials

Cambridge, MA, April 3, 2024 (Business Wire) -- Obsidian Therapeutics, Inc., a cutting-edge clinical-stage biotechnology company specializing in engineered cell and gene therapies, recently conclude

Alterome Therapeutics Raises $132M Led by Goldman Sachs for Precision Oncology Initiatives

Zura Bio Announces Robert Lisicki as CEO and Director

Obsidian Therapeutics Secures $160.5M Series C Funding for Advancement of OBX-115 Clinical Trials

Wolfgang Wienand Named New CEO of Lonza

J&J buys Shockwave for $13.1B

Capstan Therapeutics announces $175M Oversubscribed Series B Financing

Dr. David Battleman Appointed President & CEO of BioFuse Medical Technologies, Leading Advancements in Surgical Innovation

Avenzo Therapeutics announces $150M Oversubscribed Financing to Advance Emerging Oncology Pipeline

Julien Sauvagnargues Appointed CEO of Olympus Corporation of the Americas

Mirador has raised more than $400M in Financing led by ARCH Venture Partners

Executive Spotlights

Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Technology

Recent Posts

Life Science Headlines